F2RL1 and neoplasm: Furthermore, examination of the PAR-2(+)/cytoplasmic NHERF1(+) expression immunophenotype appears able to predict the prognosis of CRC and may be useful for selecting subgroups of patients who should be treated with more aggressive therapies because of the higher risk of tumour invasion and metastasis.